- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000105
Vaccination With Tetanus and KLH to Assess Immune Responses.
Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses
The purpose of this study is to learn how the immune system works in response to vaccines. We will give the vaccines to subjects who have cancer but have not had treatment, and to patients who have had chemotherapy or stem cell transplant. Some patients will get vaccines while they are on treatments which boost the immune system (like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated many patients with immune boosting drugs, we do not yet know if they improve the body's immune system to respond better to a vaccine. Some healthy volunteers will also be given the vaccines in order to serve as control subjects to get a good measure of the normal immune response. We will compare the patients and the healthy volunteers to study how their immune systems respond to the vaccines.
There are several different types of white cells in the blood. We are interested in immune cells in the blood called T-cells. These T-cells detect foreign substances in the body (like viruses and cancer cells). We are trying to learn more about how the body fights these foreign substances. Our goal is to develop cancer vaccines which would teach T-cells to detect and kill cancer cells better. We know that in healthy people the immune system effectively protects against recurrent virus infection. For example, that is why people only get "mono" (mononucleosis) once under normal circumstances. When the body is infected with the "mono" virus, the immune system remembers and prevents further infection. We are trying to use the immune system to prevent cancer relapse. To test this, we will give two vaccines which have been used to measure these immune responses. Blood samples will be studied from cancer patients and will be compared to similar samples from normal subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will receive each vaccine once only consisting of:
Arm A: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
Arm B: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
Arm C: Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (now replaced with vegetable (VG) source after 8/31/06 to increase product safety) subcutaneous Tetanus toxoid 0.5 ml intramuscularly (this arm open 3/18/03).
Subjects ineligible for tetanus may still receive KLH on this protocol. This is especially true given the national shortage of tetanus vaccines. Subjects will be eligible for tetanus when it becomes available if there has been no significant change in treatment interventions or overall health status and it is within 3 months of the KLH vaccine.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Division of Hematology, Oncology, and Transplantation 420 Delaware St., SE, Box 806 Mayo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Normal volunteers
- Patients with Cancer (breast, melanoma, hematologic)
- Transplant patients (umbilical cord blood transplant, autologous transplant)
- Patients receiving other cancer vaccines
Description
Inclusion Criteria:
- Patients must have a diagnosis of cancer of any histologic type.
- Patients must have a Karnofsky performance status great or equal to 70%.
- Patients must have an expected survival for at least four months.
- Normal healthy volunteers to serve as control for this study.
- All patients must sign informed consent approved by the Committee on the Use of Human Subjects at the University of Minnesota
Exclusion Criteria:
- Pregnant or lactating women. Females of child-bearing potential will be asked to take a pregnancy test before receiving vaccines.
- Serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the follow-up monitoring program.
- Immunization should not be administered during the course of any febrile illness or acute infection.
- Hypersensitivity to any component of the vaccine, including Thimerosal, a mercury derivative.
- The occurrence of any type of neurologic symptoms to tetanus vaccine in th past.
- Patients with a history of seafood allergy are excluded from receiving KLH.
- Subjects who have had tetanus toxoid within the last 7 years are not eligible for tetanus vaccine component of this protocol.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Arm A: Intracel KLH
Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
|
Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
Other Names:
Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Other Names:
|
Arm B: Biosyn KLH
Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
|
Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Other Names:
Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
Other Names:
|
Arm C: Biosyn KLH with Montanide ISA51
Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
|
Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Other Names:
Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
Other Names:
Emulsify the KLH with Montanide ISA-51.
The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water.
Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess whether patients can mediate an appropriate immune response KLH
Time Frame: Week 4 post vaccination
|
Week 4 post vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tetanus Response
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeffrey Miller, MD, Masonic Cancer Center, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2002LS032
- MT1999-06 (Other Identifier: Blood and Marrow Transplantation Program)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Adenocyte, LLCNot yet recruitingPancreas Cancer | Pancreatic Cyst | IPMN, Pancreatic
-
Jiangxi Provincial Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer
-
University of HullHull University Teaching Hospitals NHS TrustNot yet recruitingLocally Advanced Rectal Carcinoma
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityShenshan Medical Center, Memorial Hospital of Sun Yat-sen UniversityNot yet recruitingEpithelial Ovarian CancerChina
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingGynecologic Cancer | Surgical Procedure, UnspecifiedItaly
-
Duke UniversityNational Human Genome Research Institute (NHGRI)Not yet recruitingLiver Diseases | Cardiovascular Diseases | Cancer | HyperthermiaUnited States
-
Sun Yat-sen UniversityRecruitingNon-small Cell Lung Cancer | Cardiac ToxicityChina
-
Tongji UniversityShanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruiting
-
Xencor, Inc.Not yet recruitingTesticular Germ Cell Tumor | Ovarian Cancer | Endometrial Cancer | Ovarian Germ Cell Tumor | Germ Cell Tumor
-
Henan Cancer HospitalNot yet recruitingBreast Cancer | HER2-positive Breast CancerChina
Clinical Trials on Intracel KLH Vaccine
-
Roswell Park Cancer InstituteNot yet recruitingMalignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine NeoplasmUnited States
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)RecruitingLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
Novartis PharmaceuticalsRecruitingRelapsing Multiple SclerosisUnited States, Spain, France, Hungary, Russian Federation, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Poland, Portugal, Denmark, Japan, Israel, Taiwan, Turkey, Slovakia, United Kingdom, Argentina, Estonia, ... and more
-
University of NebraskaGenitope CorporationCompleted
-
Memorial Sloan Kettering Cancer CenterY-mAbs TherapeuticsActive, not recruiting
-
Roswell Park Cancer InstituteCelgeneActive, not recruitingPlasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell LeukemiaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Center for Complementary and Integrative...CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu PositiveUnited States
-
Roswell Park Cancer InstituteActive, not recruitingGlioblastoma | GliosarcomaUnited States
-
Hoffmann-La RocheCompletedMultiple Sclerosis, Relapsing-RemittingCanada, United States
-
University of PennsylvaniaCompletedMultiple MyelomaUnited States